Ropeginterferon alfa-2b
- Generic Name
- Ropeginterferon alfa-2b
- Brand Names
- Besremi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1335098-50-4
- Unique Ingredient Identifier
- 981TME683S
- Background
Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia. Interferon alfa-2b has been used for decades to treat PV but r...
- Indication
Ropeginterferon alfa-2b is indicated for the treatment of adult patients with polycythemia vera.
- Associated Conditions
- Polycythemia Vera (PV)
- Associated Therapies
- -
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
- Conditions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 319
- Registration Number
- NCT06506084
- Locations
- 🇮🇹
Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
🇮🇹A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy
🇮🇹UOC Ematologia, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- PharmaEssentia
- Target Recruit Count
- 150
- Registration Number
- NCT06468033
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- PharmaEssentia
- Target Recruit Count
- 70
- Registration Number
- NCT06290765
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05808322
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05494528
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- PharmaEssentia
- Target Recruit Count
- 49
- Registration Number
- NCT05485948
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳Nanfang Hospital affiliated to Southern Medical University, Guangzhou, China
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
- Conditions
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05467553
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
Ropeginterferon Alfa 2b for Early Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT04988815
- Locations
- 🇭🇰
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- PharmaEssentia Japan K.K.
- Target Recruit Count
- 36
- Registration Number
- NCT03546465
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
P1101 in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT02370329
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.